Filing Details

Accession Number:
0000899243-19-027786
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-21 16:26:43
Reporting Period:
2019-11-19
Accepted Time:
2019-11-21 16:26:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1399529 Dicerna Pharmaceuticals Inc DRNA Pharmaceutical Preparations (2834) 205993609
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1578965 Adam Koppel 200 Clarendon Street
Boston MA 02116
Yes No Yes No
1687968 Bain Capital Life Sciences Fund, L.p. 200 Clarendon Street
Boston MA 02116
No No Yes No
1702921 Bcip Life Sciences Associates, Lp 200 Clarendon Street
Boston MA 02116
No No Yes No
1702957 Lawrence Jeffrey Schwartz 200 Clarendon Street
Boston MA 02116
No No Yes No
1703030 Bain Capital Life Sciences Partners, Lp 200 Clarendon Street
Boston MA 02116
No No Yes No
1703031 Bain Capital Life Sciences Investors, Llc 200 Clarendon Street
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-11-19 1,750,000 $22.03 5,580,237 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
Footnotes
  1. On November 19, 2019 Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Capital Life Sciences Entities") sold 1,582,973 and 167,027 shares of common stock, respectively, pursuant to Rule 144 under the Securities Act of 1933, as amended.
  2. Dr. Koppel is a director of the Issuer.
  3. Bain Capital Life Sciences Partners, LP ("BC LS P") is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. BC LS P disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
  4. Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC LS P and governs the investment strategy and decision-making process with respect to investments held by BCIP LS, whose general partner is Boylston Coinvestors, LLC. As a result of the relationships described herein, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.